Mark Lakshmanan

TL;DR: The shortened time to healing for teriparatide 20 µg compared with placebo still may suggest that fracture repair can be accelerated by teriparkinide, but this result should be interpreted with caution and warrants further study.

TL;DR: Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys, and confers a lower risk of hypoglycaemia than does insulin, and is assessed in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.

TL;DR: Both once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile in type 2 diabetic patients.

TL;DR: In this paper, the incidence and severity of adverse events in postmenopausal women treated with raloxifene compared with placebo, hormone replacement therapy (HRT), or unopposed estrogen.

TL;DR: The REWIND trial's international scope, high proportion of women, highportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle‐aged patient seen in general practice throughout the world.